Skip to main content
. 2020 Oct 27;4(20):5322–5335. doi: 10.1182/bloodadvances.2020002042

Table 1.

Descriptive table of CODEG22 score in the TCGA RNA-seq training cohort (N = 173)

Parameter TCGA training cohort (N = 173) Low score subset (n = 87) High score subset (n = 86) P Test type
Sex
 Female 81 (46.8) 39 (44.8) 42 (48.8) .71 Pearson’s χ2 test
 Male 92 (53.2) 48 (55.2) 44 (51.2)
Age, median (range) 58 (18-88) 54 (18-81) 62.5 (21-88) <.001 Wilcoxon test
WBC, median (range) 17 (0.4-297.4) 13.6 (0.4-297.4) 28.3 (0.7-171.9) .13 Wilcoxon test
Blast percentage, median (range) 72 (30-100) 73 (30-100) 71.5 (30-98) .28 Wilcoxon test
Karyotype
 Abnormal karyotype 95 (55.9) 48 (55.8) 47 (56) .99 Fisher’s exact test
 Normal karyotype 75 (44.1) 38 (44.2) 37 (44)
Molecular risk groups
 Favorable 33 (19.4) 27 (31.4) 6 (7.14) <.001 Pearson’s χ2 test
 Intermediate 92 (54.1) 45 (52.3) 47 (56)
 Poor 45 (26.5) 14 (16.3) 31 (36.9)
Cytogenetic abnormalities
 Normal karyotype 75 (44.1) 38 (44.2) 37 (44) <.001 Fisher’s exact test
 t(15;17) 16 (9.41) 13 (15.1) 3 (3.57)
 t(8;21) 7 (4.12) 6 (6.98) 1 (1.19)
 Inv(16) 10 (5.88) 8 (9.3) 2 (2.38)
 Intermediate risk cytogenetics 21 (12.4) 8 (9.3) 13 (15.5)
 Complex cytogenetics 22 (12.9) 4 (4.65) 18 (21.4)
 Poor-risk cytogenetics 19 (11.2) 9 (10.5) 10 (11.9)
CN-AML mutations
 NPM1 mt 43 (57.3) 22 (57.9) 21 (56.8) .99 Pearson’s χ2 test
 NPM1 wt 32 (42.7) 16 (42.1) 16 (43.2)
 FLT3-ITD 59 (78.7) 29 (76.3) 30 (81.1) .78 Fisher’s exact test
 FLT3-ITD+ 16 (21.3) 9 (23.7) 7 (18.9)
Events
 No relapse 91 (52.6) 48 (55.2) 43 (50) .6 Pearson’s χ2 test
 Relapse 82 (47.4) 39 (44.8) 43 (50)
Survival parameters
 OS time (median), mo 18.1 56.3 8 <.001 Log-rank test
 EFS time (median), mo 9.8 20.8 5.8 <.001 Log-rank test

Data are the number of patients (percentage of entire set or subset), unless otherwise noted.

mt, nutation; wt, wild-type.